Literature DB >> 16378580

Evidence in practice--number 8. What is the prognosis of optic neuritis? How often does it lead to multiple sclerosis?

Sharon Sanders, Chris Del Mar, Sarah Purdy, Annelise Spinks, Lisa Tait, Brian McAvoy.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 16378580      PMCID： PMC1570535     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN： 0960-1643            Impact factor:   5.386


× No keyword cloud information.
  15 in total

1.  Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis.

Authors: 
Journal:  Am J Ophthalmol       Date:  2001-10       Impact factor: 5.258

2.  Feasibility of an evidence-based literature search service for general practitioners.

Authors:  C B Del Mar; C A Silagy; P P Glasziou; D Weller; A B Spinks; V Bernath; J N Anderson; D J Hilton; S L Sanders
Journal:  Med J Aust       Date:  2001-08-06       Impact factor: 7.738

3.  Predicting multiple sclerosis at optic neuritis onset.

Authors:  Y P Jin; J de Pedro-Cuesta; Y H Huang; M Söderström
Journal:  Mult Scler       Date:  2003-03       Impact factor: 6.312

4.  The prognosis of idiopathic optic neuritis.

Authors:  A Ghezzi; V Martinelli; M Rodegher; M Zaffaroni; G Comi
Journal:  Neurol Sci       Date:  2000       Impact factor: 3.307

5.  Progression of optic neuritis to multiple sclerosis: an 8-year follow-up study.

Authors:  A Druschky; J G Heckmann; D Claus; A Katalinic; K F Druschky; B Neundörfer
Journal:  Clin Neurol Neurosurg       Date:  1999-09       Impact factor: 1.876

6.  Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow-up.

Authors:  Petra Nilsson; Elna-Marie Larsson; Pia Maly-Sundgren; Roland Perfekt; Magnhild Sandberg-Wollheim
Journal:  J Neurol       Date:  2005-03-22       Impact factor: 4.849

7.  European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.

Authors:  G Comi; M Filippi; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-03       Impact factor: 10.422

8.  High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial.

Authors:  Roy W Beck; Jonathan D Trobe; Pamela S Moke; Robin L Gal; Dongyuan Xing; M Tariq Bhatti; Michael C Brodsky; Edward G Buckley; Georgia A Chrousos; James Corbett; Eric Eggenberger; James A Goodwin; Barrett Katz; David I Kaufman; John L Keltner; Mark J Kupersmith; Neil R Miller; Sarkis Nazarian; Silvia Orengo-Nania; Peter J Savino; William T Shults; Craig H Smith; Michael Wall
Journal:  Arch Ophthalmol       Date:  2003-07

9.  A reassessment of the risk of multiple sclerosis developing in patients with optic neuritis after extended follow-up.

Authors:  D A Francis; D A Compston; J R Batchelor; W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-06       Impact factor: 10.154

10.  Neurologic impairment 10 years after optic neuritis.

Authors:  Roy W Beck; Craig H Smith; Robin L Gal; Dongyuan Xing; M Tariq Bhatti; Michael C Brodsky; Edward G Buckley; Georgia A Chrousos; James Corbett; Eric Eggenberger; James A Goodwin; Barrett Katz; David I Kaufman; John L Keltner; Mark J Kupersmith; Neil R Miller; Pamela S Moke; Sarkis Nazarian; Silvia Orengo-Nania; Peyer J Savino; William T Shults; Jonathan D Trobe; Michael Wall
Journal:  Arch Neurol       Date:  2004-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.